Real World Evidence of Clinical Outcomes of First-Line Chemotherapy in Locally Advanced and Metastatic Pancreatic Adenocarcinoma Patients

Key Points

• This research examines the comparative effectiveness of first-line chemotherapy regimens in advanced pancreatic adenocarcinoma.
• Analyzed clinical outcomes of (m)FOLFIRINOX, GEM, and GEMCAPE in patients with locally advanced and metastatic disease
• Compared objective response rates and progression-free survival among different treatment groups
• (m)FOLFIRINOX showed higher objective response rates and progression-free survival compared to GEM or GEMCAPE.
• No significant survival advantage was observed for patients receiving (m)FOLFIRINOX.